(NaturalNews) FDA proposes easing clinical trial requirements for biosimilars, allowing manufacturers to rely more on lab testing rather than costly human studi…
FDA moves to fast-track biosimilars, potentially lowering drug costs — but at what cost?
Estimated read time
1 min read
